TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.100nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.300nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.300nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.300nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.400nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.5nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.600nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
Affinity DataIC50: 0.631nMAssay Description:Binding affinity to human recombinant glucocorticoid receptor expressed in baculovirus infected Sf9 cellsMore data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.700nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.700nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.700nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Binding affinity to human recombinant glucocorticoid receptor expressed in baculovirus infected Sf9 cellsMore data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Binding affinity to human recombinant glucocorticoid receptor expressed in baculovirus infected Sf9 cellsMore data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 1nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 1.10nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 1.10nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 1.10nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 1.20nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
Affinity DataIC50: 1.26nMAssay Description:Binding affinity to human recombinant mineralocorticoid receptor expressed in baculovirus infected Sf9 cellsMore data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 1.5nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 1.5nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
Affinity DataIC50: 1.58nMAssay Description:Transrepression activity at glucocorticoid receptor-mediated antiinflammatory activity in human HeLa cells assessed as inhibition of TPA-induced coll...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 1.80nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 1.90nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 1.90nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Transrepression activity at glucocorticoid receptor-mediated antiinflammatory activity in human HeLa cells assessed as inhibition of TPA-induced coll...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 2nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 2.10nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 2.30nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 2.40nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 2.5nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
Affinity DataIC50: 2.51nMAssay Description:Transrepression activity at glucocorticoid receptor-mediated antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced IL-8...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 2.70nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 2.90nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 2.90nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 2.90nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 2.90nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 3nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
Affinity DataIC50: 3.16nMAssay Description:Transrepression activity at glucocorticoid receptor-mediated antiinflammatory activity in human HeLa cells assessed as inhibition of TPA-induced coll...More data for this Ligand-Target Pair
Affinity DataIC50: 3.16nMAssay Description:Binding affinity to human recombinant glucocorticoid receptor expressed in baculovirus infected Sf9 cellsMore data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 3.20nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 3.5nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 3.80nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 3.90nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 4nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 4nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 4nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 4nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 4.10nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMAP kinase-interacting serine/threonine-protein kinase 1(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 4.10nMAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair